ArticleMaterials today. Bio2026
The mitophagy targeted nano-assemblies with high Salvianolic acid B -loading sufficiently enhances osteoarthritis therapy.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is characterized by chondrocyte degeneration and associated intracellular organelle dysfunction. Restoring impaired mitophagy represents a critical strategy for ameliorating OA-induced chondrocyte dysfunction and promoting cartilage repair, yet a significant therapeutic gap persists due to the lack of highly potent agents that can effectively restore mitophagy in OA chondrocyte. In this work, we identified Salvianolic acid B (SaB), a novel small-molecule agent, which binds to PINK1/Parkin proteins to stabilize them, promote their expression, and activate mitophagy. SaB nano-assemblies (SaB NAs) were fabricated via hydrogen bonding and π-π stacking between SaB and triphenylphosphine, achieving exceptional drug loading (74.4%) and mitochondrial-targeted synergistic therapeutic effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.